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BACKGROUND Implantable cardioverter-deﬁbrillators (ICDs) are
effective in terminating lethal arrhythmias, but little is known about
the degree of health care utilization (HCU) after ICD therapies.
OBJECTIVE Using data from the managed ventricular pacing trial,
we sought to identify the incidence and types of HCU in ICD patients
after receiving ICD therapy (shocks or antitachycardia pacing [ATP]).
METHODS We analyzed HCU events (ventricular tachyarrhythmia
[VTA]–related, heart failure–related, ICD implant procedure–related,
ICD system–related, or other) and their associationwith ICD therapies
(shocked ventricular tachycardia episode, ATP-terminated ventricular
tachycardia episode, and inappropriately shocked episode).
RESULTS A total of 1879 HCUs occurred in 695 of 1030 subjects
(80% primary prevention) and were classiﬁed as follows: 133
(7%) VTA-related, 373 (20%) heart failure–related, 97 (5%) implant
procedure–related, 115 (6%) system-related, and 1160 (62%)
other. Of 2113 treated VTA episodes, 1680 (80%) received ATP
only and 433 (20%) received shocks. Stratifying VTA-related HCUs
on the basis of the type of ICD therapy delivered, there were 25
HCUs per 100 shocked VTA episodes compared with 1 HCU per 100
ATP-terminated episodes. Inappropriate ICD shocks occurred in
8.7% of the subjects and were associated with 115 HCUs. The major-
ity of HCUs (52%) began in the emergency department, and 66% of
all HCUs resulted in hospitalization.
CONCLUSION For VTA-related HCUs, shocks are associated with a
25-fold increase in HCUs compared to VTAs treated by ATP only.
Application of evidence-based strategies and automated device–
based algorithms to reduce ICD shocks (higher rate cutoffs, use of
ATP, and arrhythmia detection) may help reduce HCUs.
KEYWORDS Health care utilization; ICD; Shocks; ATP; Hospitaliza-
tion; MVP
(Heart Rhythm 2017;14:1382–1387) © 2017 The Authors. Pub-
lished by Elsevier Inc. on behalf of Heart Rhythm Society. This is
an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Implantable cardioverter-deﬁbrillators (ICDs) have been shown
to reduce all-cause mortality in patients with systolic heart fail-
ure (HF).1–3 Since their introduction over 30 years ago, ICD
implant procedures have increased4 and greater use of resources
have been required for routine care, especially soon after ICD
therapies have been delivered. The latter events have resulted
in unscheduled visits to hospitals, emergency departments
(EDs), and clinics, but the extent to which these services have
been used remains poorly understood. Understanding this in
the present era of cost containment is critical in an effort to iden-
tify ways to improve health care efﬁciency. The purpose of this
investigationwas to characterize health care utilizations (HCUs)
in patients receiving ICD therapies, speciﬁcally focusing on dif-
ferences between shocks and antitachycardia pacing (ATP) as
well as venues of care (ED vs outpatient clinics).
Methods
Study design and participants
This is a post hoc analysis of data collected in the random-
ized, multicenter managed ventricular pacing (MVP) trial.5
Brieﬂy, patients aged 18 years and older who underwent a
primary or secondary prevention ICD implant procedure
per current clinical guidelines were enrolled from 2004 to
2006 at 84 centers globally and followed for up to 3 years
from device implant. Patients with a need for pacing, in
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permanent atrial ﬁbrillation, or having a life expectancy of
,12 months were excluded. Ventricular tachyarrhythmias
(VTAs), device therapies, and utilization of health care ser-
vices were collected. An ethics committee approved the
MVP protocol at each participating center, and all subjects
provided signed informed consent.
Device programming
ICD programming was standardized. Devices were pro-
grammed to detect VTAs .171 beats/min for those with
known slow ventricular tachycardia and .176 beats/min
otherwise, with the number of intervals to detect ventricular
ﬁbrillation set to 18/24. Arrhythmias between 171 and 200
beats/min received ATP as the ﬁrst 2 therapies, followed
by shocks if necessary. Arrhythmias between 200 and 250
beats/min received ATP as the ﬁrst therapy, followed by
shocks if necessary.
Data collection
Demographic data were obtained at the baseline visit.
Adverse events, HCUs, and arrhythmias stored on subjects’
devices were collected during follow-up. HCUs included un-
scheduled clinic and urgent care visits, ED visits, and hospi-
talizations. Adverse events were deﬁned as any undesirable
clinical occurrence in a subject that is related to the subject’s
cardiovascular, pulmonary, or renal system or events in
which the subject presented with symptoms compatible
with ﬂuid retention and/or decreased exercise tolerance. All
available device-recorded spontaneous arrhythmias with
electrogram information were adjudicated by an episode
review committee as true VTA or non-VTA (eg, sinus
tachycardia, atrial ﬁbrillation, and oversensing).
End points
The ﬁrst end point evaluated was the type of HCU. HCUs
were classiﬁed as (1) VTA-related, (2) HF-related, (3) ICD
implant procedure–related (such as pneumothorax or hema-
toma), (4) ICD system–related (including HCUs related to
inappropriate shocks or system modiﬁcations), or (5) other
(not related to HF or device). The second end point was the
type of ICD therapy–related HCUs experienced by subjects,
classiﬁed as related to a (1) shocked VTA episode, (2) ATP-
terminated VTA episode, or (3) shocked non-VTA episode
(inappropriately shocked). HCUs related to inappropriate
shocks were considered a subclassiﬁcation of ICD system–
related HCUs for this analysis. End points were adjudicated
by an independent adverse events committee and a subset
of the MVP Steering Committee.
ICD therapy–related HCUs
VTAs were classiﬁed into the following subcategories (for
the second end point of ICD therapy–related HCU types):
 Shocked VTA episode
 ATP-terminated VTA episode
 Untreated VTA
 Shocked non-VTA episode (inappropriately shocked)
Episodes that received both ATP and shocks were consid-
ered shocked VTA episodes. The committee reviewed all
HCUs with corresponding documentation of arrhythmia or
device therapy occurrence or for which the subject experi-
enced an arrhythmia or device therapy 30 days prior. Adverse
events, the 30-day history of device-detected and treated ep-
isodes, ﬁnal episode adjudication from the episode review
committee (VTA or non-VTA), and the HCU narrative
were used to determine whether the HCU was related to
device therapy.
Final classiﬁcation of HCU type
The ﬁnal classiﬁcation of HCU relatedness for both end
points were established hierarchically: (1) VTA with sub-
classes of (a) shocked, (b) ATP terminated, and (c) untreated;
(2) HF; (3) ICD implant procedure; (4) ICD system
(including inappropriate shock); or (5) other.
Table 1 Baseline demographic characteristics (N 5 1030)
Characteristic Value
Age (y) 62.2 6 11.9
Sex: male 819 (79.5)
NYHA classiﬁcation
Class I 262 (25.4)
Class II 567 (55)
Class III 193 (18.7)
Class IV 2 (0.2)
LVEF (%) 34.8 6 11.9
Dilated cardiomyopathy 859 (83.4)
Ischemic 644 (62.5)
Nonischemic 215 (20.9)
Sinus node dysfunction 40 (3.9)
Left bundle branch block 127 (12.3)
Right bundle branch block 84 (8.2)
Intraventricular conduction delay 32 (3.1%)
AV block (most recent) 170 (16.5)
First degree block 156 (15.1)
Second degree block 7 (0.7)
Third degree block 1 (0.1)
Supraventricular tachyarrhythmias 177 (17.2)
Paroxysmal supraventricular tachyarrhythmia 33 (3.2)
Atrial tachycardia 16 (1.6)
Atrial ﬁbrillation, atrial ﬂutter 141 (13.7)
Persistent 10 (1)
Paroxysmal 131 (12.7)
Ventricular tachyarrhythmias 455 (44.2)
Nonsustained VT 260 (25.2)
Sustained monomorphic VT 149 (14.5)
Sustained polymorphic VT 6 (0.6)
Unspeciﬁed sustained VT 16 (1.6)
Torsades de pointes 4 (0.4)
Ventricular ﬁbrillation, ventricular
ﬂutter, cardiac arrest
82 (8)
ACE inhibitors or ARBs 850 (82.5)
b-Blockers 914 (88.7)
Diuretics 557 (54.1)
Amiodarone/sotalol 133 (12.9)
Reason for ICD therapy: primary indication 829 (80.5)
Values are presented as mean 6 SD or as n (%).
ACE 5 angiotensin-converting enzyme; ARB 5 angiotensin receptor
blocker; AV 5 atrioventricular; ICD 5 implantable cardioverter-
deﬁbrillator; LVEF 5 left ventricular ejection fraction; NYHA 5 New York
Heart Association; VT 5 ventricular tachycardia.
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Statistics
Descriptive statistics were used to summarize baseline demo-
graphic characteristics. Percentages were used to show the
HCU types experienced by subjects. Cumulative incidence
curves accounting for the competing risk of all-cause mortal-
ity were generated to compare onset of treated and, specif-
ically, shocked VTA with HCUs related to appropriate
VTA therapy. Rates at annual time points are reported along
with 95% conﬁdence intervals. Annual rates were used to
summarize the prevalence of different types of HCUs (eg,
HF-related and VTA-related). Subjects were censored at the
time of their last device interrogation for the calculation of
rates of arrhythmic episodes. The data analysis for this article
was performed using SAS/STAT software version 13.1 of the
SASSystem forWindows. The cumulative incidence rate was
obtained with S-PLUS software version 8.2 for Windows.
Results
This analysis included 1030 subjectswho had completeHCU-
related data, of which 824(80%) had primary prevention
indication. The complete baseline characteristics are
summarized in Table 1 and are similar to those of prior ICD
clinical studies. During a mean follow-up of 2.4 years, 1879
HCUs occurred in 695 subjects (68%). Among them, 358
HCUs (19%) were identiﬁed for further adjudication because
they were ﬂagged as being VTA or ICD therapy–related on
the clinical report form or because the patient had experienced
a VTA or ICD therapy within 30 days before the HCU. Of the
358 HCUs, 206 (57.5%)were related to VTA or shocks. With
respect to treated arrhythmias, there were 2113 episodes of
treated VTAs in 222 subjects (22%) and 616 episodes of
treated non-VTAs in 125 subjects (12%). Of all treated
VTA episodes, 1680 (80%) received ATP only and 433
(20%) received shocks. There were an additional 1219 treated
episodes in 51 subjects not adjudicated because of missing
electrograms.
HCU incidence rate and types
The 1879 observed HCUs were classiﬁed as follows: 133
VTA-related, 373 HF-related, 97 implant procedure–related,
115 system-related, 1 related to shock of unknown origin, and
1160 other (Table 2). The vast majority of HCUs (89%) were
unrelated to VTA or inappropriate shocks. Examples
included HCUs for myocardial infarction, transient ischemic
attack, and chronic obstructive pulmonary disease. Annual
rates for each HCU type in different follow-up intervals are
shown in Figure 1, which illustrates that the frequency of
therapy-related HCUs are highest in the 6 months after ICD
implantation and remain fairly constant thereafter.
ICD therapy–related HCUs
During follow-up, 206 VTA and/or therapy-related HCUs of
the following types occurred in 139 subjects: 110 (53%) for
shocked VTA episodes, 11 (5%) for ATP-terminated VTA
episodes (nonshocked VTA), 12 (6%) for untreated VTA
or VTA in which the therapy relatedness was unknown, 72
(35%) for inappropriately shocked episodes, and 1 for a
shocked episode with unknown VTA status. ATP-related
HCUs were due to dizziness/syncope, palpitations, chest
Table 2 Summary of VTA, shock, HF, procedure, and system
relatedness of HCUs (N 5 1030)
Relatedness
No. of HCUs
(No. of subjects)
VTA 133 (82)
Shocked VTA 110 (74)
Nonshocked VTA* 23 (19)
Shocked non-VTA (inappropriate shocks) 72 (62)
Shocked episode (unknown if VTA) 1 (1)
Heart failure–related and not VTA-related 373 (193)
Associated with procedure-related AE only 97 (76)
Associated with system-related AE only 43 (36)
Other 1160 (511)
Total 1879 (695)
AE 5 adverse event; ATP 5 antitachycardia pacing; HCU 5 health care
utilization; HF 5 heart failure; VTA 5 ventricular tachyarrhythmia.
*Reﬂects ATP-terminated VTA, untreated VTA, and VTA for which therapy
relatedness was unknown.
Figure 1 Annual rates for HCUs in each of the 6 periods after the implant procedure. Only HCUs relatedness to VTA, ICD therapy, heart failure, implant
procedure, or the ICD system are included. HCU 5 health care utilization; ICD 5 implantable cardioverter-deﬁbrillator; VTA 5 ventricular tachyarrhythmia.
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discomfort, or, in 1 case, a phantom shock. The percentage of
patients experiencing ventricular arrhythmias and ventricular
arrhythmia–related HCUs is presented in Figure 2 and
Table 3. During 36 months, 8.7% of subjects had a VTA-
related HCU and 10.3% had an inappropriately shocked
episode. Only 1.2% of the study population had an HCU
related to an ATP-terminated VTA episode, whereas 7.9%
were estimated to have had a shocked VTA-related HCU
and 7.1% had an inappropriate shock–related HCU. HCUs
from a shocked VTA resulted in a dramatic increase in
HCUs compared with a VTA treated with ATP. In fact, for
every 100 VTAs treated with an ICD shock, there were 25
HCUs as compared with 1 HCU event for every 100 VTAs
treated with ATP. The elevated HCU rate was also observed
for inappropriate shocks. For every 100 incidents of inappro-
priate shock, there were 30 HCUs.
Location of ICD therapy–related HCUs
The majority of ICD therapy–related HCUs started in the ED
(59%), and most resulted in hospitalization (65%) (Table 4).
Seven percent of shock-related HCUs started in the hospital
compared with 21% of HCUs unrelated to VTA or ICD ther-
apy. The hospital was the most frequent ﬁnal location of
shock-related HCUs (64%), followed by the clinic (21%)
and ED (14%). Sixty-ﬁve percent of shocked VTA-related
HCUs, 64% of inappropriate shock–related HCUs, and
57% of ATP-terminated or self-terminated VTA-related
HCUs resulted in hospitalization (Table 4). Most (106 of
182 [58%]) shock-related HCUs occurred in .1 location
(eg, presented in the ED and then hospitalized).
Discussion
This analysis has provided 3 important insights in our under-
standing of HCU after ICD therapies. First, 89% of HCUs in
typical ICD subjects are not related to the device with 20%
related to HF and 10.4% related to device therapy. Second,
shocks generate signiﬁcantly more HCUs compared with
VTA episodes terminated by ATP only. Lastly, the majority
of ICD shocks result in ED visits followed by hospitalization.
Figure 2 Cumulative incidence rate for ﬁrst VTA, VTA treated with antitachycardia pacing or shock, VTA treated with shock, VTA-related HCU, and shocked
VTA-related HCU accounting for competing risk of mortality. HCU 5 health care utilization; VTA 5 ventricular tachyarrhythmia.
Table 3 Cumulative incidence rates for VTA and HCU end points at 12, 24, and 36 mo after the implant procedure
End point
Cumulative incidence rate (%) (95% conﬁdence interval)*
12 mo 24 mo 36 mo
VTA 18.0 (15.7–20.5) 27.1 (24.5–29.9) 31.1 (27.6–35.1)
Treated VTA 14.2 (12.2–16.4) 21.0 (18.7–23.7) 24.8 (22.1–27.7)
Shocked VTA 7.2 (6.0–8.8) 10.3 (8.6–12.3) 12.0 (10.0–14.5)
VTA-related HCU 5.1 (4.0–6.4) 7.5 (6.0–9.4) 8.7 (7.1–10.8)
Shocked VTA-related HCU 4.6 (3.5–6.1) 6.7 (5.2–8.6) 7.9 (6.4–9.8)
HCU 5 health care utilization; ICD 5 implantable cardioverter-deﬁbrillator; VTA 5 ventricular tachyarrhythmia.
*Cumulative incidence rates represent the estimated percentage of subjects experiencing the end point at 12, 24, and 36 mo after the ICD implant procedure.
Rates were calculated using time-to-event methods accounting for mortality as a competing risk.
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There are limited data on HCU after ICD therapy. Bhav-
nani et al6 showed a signiﬁcant difference in health care costs
associated with inappropriate shock (compared to no shocks)
within a year after device implant. Taken together, appro-
priate and inappropriate ICD shocks frequently result in
health care system utilization and subsequent costly testing.
In the current study, we similarly show that a signiﬁcant num-
ber of shock events ultimately lead to an HCU. A similar
ﬁnding, however, was not noted for ATP events where the
large majority did not lead to an HCU. ATP therapy has
been shown to terminate most ventricular tachycardia epi-
sodes and potentially improve quality of life compared
with ICD shocks.7
While reducing shocks and hence HCUs is an important
goal, our study shows that the majority of HCUs in patients
with ICD are not related to their device. While reducing
shocks will likely result in reduced HCUs, dramatic reduc-
tions are unlikely given multiple other comorbid conditions.
The potential to use device diagnostics to decrease HF-
related HCUs is an appealing idea. Although still a minority
of overall HCUs at 20%, HF-related HCUs remain an impor-
tant target for cost reduction. Understanding ways in which to
reduce these events remains paramount.
Our study also found that patients who seek care after a
shock primarily present to the ED, which often leads to inpa-
tient hospitalization. While individual practices vary, often
single shock episodes can be managed by a device clinic
either the same or the next day in clinic rather than necessi-
tating ED care. Given the costly nature of ED and inpatient
hospital care, our data suggest that there may be room for
cost reduction via patient education in how single shock
episodes are managed.
Study limitations
Our study has several limitations. First, this was a post hoc
analysis of a randomized clinical study. Hence, all limitations
associated with this type of analysis need to be considered.
Second, the time period from when the MVP trial was con-
ducted predated multiple trials where prolonged detection in-
tervals, higher rate cutoffs, and improved detection
algorithms were used. While shocks are less likely with
modern-day programming,8-11 the correlation between
shocks and HCU is likely similar.
Conclusion
Overall, the majority of HCUs in the population with ICD are
not related to their device. For device-related HCUs, shocks
generate signiﬁcantly more HCUs compared to VTAs termi-
nated by ATP. Lastly, HCUs using the ED commonly result
in hospitalization. Application of evidence-based strategies
to reduce ICD shocks, such as higher rate cutoffs, use of
ATP, improved patient counseling for postshock care, and
detection algorithms, may help reduce therapy-related
HCUs and shift them from higher to lower cost venues.
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Table 4 Summary of VTA and device therapy relatedness of HCUs
by HCU type (N 5 1030)
Relatedness
No. of HCUs
(No. of subjects)
Shocked VTA 110 (74)
Clinic visit only 21 (15)
ED visit only 17 (14)
Clinic and ED visit 1 (1)
Hospitalization 71 (56)
Hospitalization only 6 (5)
Clinic visit and hospitalization 10 (10)
ED visit and hospitalization 51 (41)
Clinic visit, ED visit, and hospitalization 4 (4)
Nonshocked VTA (or therapy
relatedness unknown)
23 (19)
Clinic visit only 7 (6)
ED visit only 1 (1)
Clinic and ED visit 2 (1)
Hospitalization 13 (13)
Hospitalization only 2 (2)
Clinic visit and hospitalization 1 (1)
ED visit and hospitalization 9 (9)
Clinic visit, ED visit, and hospitalization 1 (1)
Shocked non-VTA (inappropriate shocks) 72 (62)
Clinic visit only 17 (16)
ED visit only 9 (9)
Clinic and ED visit 0 (0)
Hospitalization 46 (42)
Hospitalization only 6 (5)
Clinic visit and hospitalization 8 (8)
ED visit and hospitalization 31 (30)
Clinic visit, ED visit, and hospitalization 1 (1)
Shocked episode (unknown if VTA) 1 (1)
Other relatedness to VTA or shocks 4 (4)
Not related to shocks, ATP, or VTA 1669 (639)
Clinic visit only 295 (175)
ED visit only 252 (158)
Clinic and ED visit 7 (7)
Hospitalization 355 (261)
Hospitalization only 355 (261)
Clinic visit and hospitalization 126 (98)
ED visit and hospitalization 594 (324)
Clinic visit, ED visit, and hospitalization 40 (33)
Total 1879 (695)
Clinic visit only 341 (197)
ED visit only 281 (175)
Clinic and ED visit 10 (8)
Hospitalization 1247 (584)
Hospitalization only 369 (270)
Clinic visit and hospitalization 145 (113)
ED visit and hospitalization 687 (365)
Clinic visit, ED visit, and hospitalization 46 (38)
Other includes cases in which relatedness to all 3 categories (VTA, device
therapy, and shocks) was unknown (n5 1), HCU was related to device ther-
apy but shock and VTA relatedness unknown (n 5 1), or HCU was related to
ATP-terminated non-VTA (n 5 1).
ATP 5 antitachycardia pacing; ED 5 emergency department;
HCU 5 health care utilization; VTA 5 ventricular tachyarrhythmia.
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